Depomed Announces Initiation of Phase 2 Clinical Study in Parkinson's Disease
Depomed, Inc. (Nasdaq: DEPO) today announced that it has initiated a Phase 2 clinical trial of DM-1992, Depomed's novel gastric-retentive, extended-release formulation of carbidopa/levodopa, in patients with advanced Parkinson's disease with motor fluctuations.







